Stockscreener 앱 받기
18.66
5.78%
1.02
시간 외 거래:
18.72
0.06
+0.32%
전일 마감가:
$17.64
열려 있는:
$17.36
하루 거래량:
1.44M
Relative Volume:
1.33
시가총액:
$1.86B
수익:
-
순이익/손실:
$-183.79M
주가수익비율:
-9.0184
EPS:
-2.0691
순현금흐름:
$-131.84M
1주 성능:
+3.78%
1개월 성능:
+8.05%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$17.25
$18.82
1주일 범위
$17.25
$18.82
52주 변동 폭
$14.62
$19.62
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
18.66 | 1.76B | 0 | -183.79M | -131.84M | -2.0691 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design - Yahoo Finance
Superstring Capital's Definium Therapeutics Investment: Q4 2025 PositionNews and Statistics - IndexBox
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
DFTX: Pivotal phase III data for DT-120 in GAD and MDD expected this year, targeting broad market impact - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 earnings call transcript - MSN
Definium Therapeutics stock hits 52-week high at 18.71 USD By Investing.com - Investing.com Nigeria
Boxer Capital Management LLC Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference - MarketBeat
Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX - MarketBeat
Rosalind Advisors Inc. Has $8.84 Million Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
DFTX: Phase III data for DT120 in GAD and MDD expected in 2024, targeting major unmet needs - TradingView
DFTX: Three pivotal data readouts for GAD and MDD expected in 2024, with strong Phase II results - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.71 USD - Investing.com Australia
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighHere's Why - MarketBeat
Definium Therapeutics Announces New Employee Inducement Grants - National Today
New Definium hires receive stock options and performance shares - Stock Titan
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (2026-03-09) - Seeking Alpha
How Definium’s Widening 2025 Loss Will Impact Definium Therapeutics (DFTX) Investors - simplywall.st
Royce & Associates LP Invests $955,000 in Definium Therapeutics, Inc. $DFTX - MarketBeat
Equities Analysts Set Expectations for DFTX Q1 Earnings - Defense World
Q1 EPS Forecast for Definium Therapeutics Cut by Analyst - MarketBeat
Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX) - The Globe and Mail
A Look At Definium Therapeutics (DFTX) Valuation As Wider Full Year Loss Refocuses Investor Expectations - simplywall.st
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - simplywall.st
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts’ Top Healthcare Picks: Definium Therapeutics (DFTX), Lantheus (LNTH) - The Globe and Mail
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - Newswire Canada
Is Rising 2025 Loss and Investor Outreach Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising R&D Costs - GuruFocus
Decoding Definium Therapeutics Inc (DFTX): A Strategic SWOT Insi - GuruFocus
Definium Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Definium Therapeutics Q4 2025 reports strong R&D investment By Investing.com - Investing.com South Africa
Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Definium Therapeutics Issues Inducement Stock Options to New Hires - TipRanks
Definium Therapeutics Inc: Four pivotal phase III studies near completion, with strong cash reserves and key data readouts ahead - TradingView
Definium Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Definium Therapeutics posts full-year 2025 financial results, releases business update - Traders Union
Definium Therapeutics Inc (DFTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):